

Docket No: A0848.70011US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LAEREMANS et al.  
Int'l Application No. : PCT/BE2003/000189  
Int'l Filing Date : 07 November 2003 (07.11.2003)  
Title : CAMELIDAE SINGLE DOMAIN ANTIBODIES VHH  
DIRECTED AGAINST EPIDERMAL GROWTH FACTOR  
RECEPTOR AND USES THEREFOR

---

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application.

No fee or certification is required.

**PART II: Information Cited**

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

**International Search Report** for Application No. PCT/BE03/00189, filed November 7, 2003 (copy enclosed).

Int'l Application No. PCT/BE03/00189  
Docket No. A0848.70011US00

Int'l. Filing Date: 7 November 2003

Page 2

1020 PCT/BE03/00189 12 OCT 2003

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,  
*Laeremans, et al., Applicant*



John R. Van Amsterdam, Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Telephone: (617) 646-8000

Docket No. A0848.70011US00  
Dated: October 12, 2005  
**xNDDx**  
946309.1

FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: Not yet assigned		DOCKET NO. A0848.70011US00	
		INT'L. FILING DATE: 11/07/03		Confirmation No. <b>10/553105</b>	
		APPLICANT: Laeremans, et al.			
		GROUP ART UNIT: Unknown		EXAMINER: Unknown	
Sheet	1	of	1		

**U.S. PATENT DOCUMENTS**

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	2002/058033	A1	Raisch, et al.	05-16-2002
	A2	2003/092892	A1	Frenken, et al.	05-15-2003

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	ARBABI GHAHROUDI, et al., "Selection and Identification of single domain antibody fragments from camel heavy-chain antibodies," FEBS letters, Elsevier Science Publishers, Vol. 414, No. 3, September 15, 1997, pgs. 521-526	
	C2	CORTEZ-RETAMOZO V., et al., "Efficient tumor targeting by single-domain antibody fragments of camels," International Journal of Cancer, Vol. 98, No. 3, pgs. 456-462, March 20, 2002	
	C3	TAHA, J., et al., "Selection by phage display of llama conventional VH fragments with heavy chain antibody VHH properties," Journal of Immunological Methods, Vol. 263, No. 1-2, May 1, 2002, pgs. 97-109	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No., filed , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications.]